{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:12:03Z","timestamp":1792761123184,"version":"4.5.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s43440-025-00818-2","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T01:16:32Z","timestamp":1767575792000},"page":"27-44","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The role of pharmacogenetics in the therapy regimen of acute lymphoblastic leukemia in children: recent discoveries and future perspectives"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4848-9012","authenticated-orcid":false,"given":"Anna","family":"Szoszkiewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2379-3969","authenticated-orcid":false,"given":"Alina","family":"\u015awiat\u0142owska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7239-4035","authenticated-orcid":false,"given":"Katarzyna","family":"Derwich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4058-3901","authenticated-orcid":false,"given":"Aleksander","family":"Jamsheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1730-0176","authenticated-orcid":false,"given":"B\u0142a\u017cej","family":"Rubi\u015b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7272-5738","authenticated-orcid":false,"given":"Agnieszka","family":"Bienert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"818_CR1","doi-asserted-by":"crossref","unstructured":"Pagliaro L, Chen SJ, Herranz D, Mecucci C, Harrison CJ, Mullighan CG, et al. Acute lymphoblastic leukaemia. Nat Rev Dis Primers. 2024;13(1):41.","DOI":"10.1038\/s41572-024-00525-x"},{"key":"818_CR2","doi-asserted-by":"publisher","first-page":"1082789","DOI":"10.3389\/fonc.2023.1082789","volume":"13","author":"G Abdulaziz-Opiela","year":"2023","unstructured":"Abdulaziz-Opiela G, Sobieraj A, P\u0142otka A, Wi\u0119ckowska B, Gil L, Derwich K. Comparison of diagnostic and treatment processes among pediatric and adolescents and young adults\u2019 populations suffering from acute lymphoblastic leukemia and lymphomas. Front Oncol. 2023;13:1082789.","journal-title":"Front Oncol"},{"key":"818_CR3","unstructured":"Childhood Acute Lymphoblastic Leukemia Treatment (PDQ\u00ae) - NCI [Internet]. 2025 [cited 2025 Aug 25]. Available from: https:\/\/www.cancer.gov\/types\/leukemia\/hp\/child-all-treatment-pdq"},{"issue":"2","key":"818_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.gpb.2016.11.003","volume":"15","author":"S Rudin","year":"2017","unstructured":"Rudin S, Marable M, Huang RS. The promise of pharmacogenomics in reducing toxicity during acute lymphoblastic leukemia maintenance treatment. Genomics Proteom Bioinf. 2017;15(2):82\u201393.","journal-title":"Genomics Proteom Bioinf"},{"issue":"3","key":"818_CR5","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/genes10030191","volume":"10","author":"S Pavlovic","year":"2019","unstructured":"Pavlovic S, Kotur N, Stankovic B, Zukic B, Gasic V, Dokmanovic L. Pharmacogenomic and Pharmacotranscriptomic profiling of childhood acute lymphoblastic leukemia: paving the way to personalized treatment. Genes. 2019;10(3):191.","journal-title":"Genes"},{"key":"818_CR6","doi-asserted-by":"crossref","unstructured":"Ceppi F, Langlois-Pelletier C, Gagn\u00e9 V, Rousseau J, Ciolino C, De Lorenzo S, et al. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014;15(8):1105\u201316.","DOI":"10.2217\/pgs.14.68"},{"key":"818_CR7","doi-asserted-by":"crossref","unstructured":"Li L, Sajdyk T, Smith EML, Chang CW, Li C, Ho RH, et al. Genetic variants associated with vincristine-induced peripheral neuropathy in two populations of children with acute lymphoblastic leukemia. Clin Pharmacol Ther. 2019;105(6):1421\u20138.","DOI":"10.1002\/cpt.1324"},{"key":"818_CR8","doi-asserted-by":"publisher","first-page":"1278769","DOI":"10.3389\/fphar.2023.1278769","volume":"14","author":"G Burgue\u00f1o-Rodr\u00edguez","year":"2023","unstructured":"Burgue\u00f1o-Rodr\u00edguez G, M\u00e9ndez Y, Olano N, Schelotto M, Castillo L, Soler AM, et al. Pharmacogenetics of pediatric acute lymphoblastic leukemia in uruguay: adverse events related to induction phase drugs. Front Pharmacol. 2023;14:1278769.","journal-title":"Front Pharmacol"},{"issue":"8","key":"818_CR9","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jama.2015.0894","volume":"313","author":"B Diouf","year":"2015","unstructured":"Diouf B, Crews KR, Lew G, Pei D, Cheng C, Bao J, et al. Association of an inherited genetic variant with Vincristine-Related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA. 2015;313(8):815.","journal-title":"JAMA"},{"issue":"3","key":"818_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/pbc.22845","volume":"56","author":"A Egbelakin","year":"2011","unstructured":"Egbelakin A, Ferguson MJ, MacGill EA, Lehmann AS, Topletz AR, Quinney SK, et al. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;56(3):361\u20137.","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"818_CR11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2217\/pgs-2016-0001","volume":"17","author":"E Lopez-Lopez","year":"2016","unstructured":"Lopez-Lopez E, Gutierrez-Camino A, Astigarraga I, Navajas A, Echebarria-Barona A, Garcia-Miguel P, et al. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia. Pharmacogenomics. 2016;17(7):731\u201341.","journal-title":"Pharmacogenomics"},{"issue":"2","key":"818_CR12","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/cpt.1179","volume":"105","author":"GEB Wright","year":"2019","unstructured":"Wright GEB, Amstutz U, Dr\u00f6gem\u00f6ller BI, Shih J, Rassekh SR, Hayden MR, et al. Pharmacogenomics of Vincristine-Induced peripheral neuropathy implicates Pharmacokinetic and inherited neuropathy genes. Clin Pharmacol Ther. 2019;105(2):402\u201310.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"818_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.14715\/cmb\/2019.65.2.2","volume":"65","author":"N Mehrvar","year":"2019","unstructured":"Mehrvar N, Akbari ME, Rezvany MR, Abolghasemi H, Saberynejad J, Mehrvar A, et al. ATP-Binding cassette transporters\u2019 gene expression in pediatric patients with acute leukemia; a comprehensive analysis of published reports through pubmed search engine. Cell Mol Biol Noisy\u2013Gd Fr. 2019;65(2):7\u201313.","journal-title":"Cell Mol Biol Noisy\u2013Gd Fr"},{"key":"818_CR14","doi-asserted-by":"crossref","unstructured":"Zheng Y, Ma L, Sun Q, Clinically-Relevant ABC. Transporter for Anti-Cancer Drug Resistance. Front Pharmacol. 2021;12:648407. https:\/\/www.frontiersin.org\/journals\/pharmacology\/articles\/10.3389\/fphar.2021.648407\/full","DOI":"10.3389\/fphar.2021.648407"},{"issue":"15","key":"818_CR15","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.2217\/pgs-2018-0093","volume":"19","author":"R Abaji","year":"2018","unstructured":"Abaji R, Ceppi F, Patel S, Gagn\u00e9 V, Xu CJ, Spinella JF, et al. Genetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identified using Whole-Exome sequencing. Pharmacogenomics. 2018;19(15):1181\u201393.","journal-title":"Pharmacogenomics"},{"issue":"1","key":"818_CR16","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1038\/s41467-024-48124-4","volume":"15","author":"KR Bhattarai","year":"2024","unstructured":"Bhattarai KR, Mobley RJ, Barnett KR, Ferguson DC, Hansen BS, Diedrich JD, et al. Investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment. Nat Commun. 2024;15(1):3681.","journal-title":"Nat Commun"},{"issue":"11","key":"818_CR17","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/S1470-2045(10)70114-5","volume":"11","author":"H Inaba","year":"2010","unstructured":"Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010;11(11):1096\u2013106.","journal-title":"Lancet Oncol"},{"key":"818_CR18","doi-asserted-by":"crossref","unstructured":"Gasic V, Zukic B, Stankovic B, Janic D, Dokmanovic L, Lazic J et al. Pharmacogenomic markers of glucocorticoid response in the initial phase of remission induction therapy in childhood acute lymphoblastic leukemia. Radiol Oncol. 2018 Sept 11;52(3):296\u2013306.","DOI":"10.2478\/raon-2018-0034"},{"key":"818_CR19","doi-asserted-by":"crossref","unstructured":"Xue L, Li C, Wang Y, Sun W, Ma C, He Y, et al. Single nucleotide polymorphisms in non-coding region of the glucocorticoid receptor gene and prednisone response in childhood acute lymphoblastic leukemia. Leuk Lymphoma. 2015;56(6):1704\u20139.","DOI":"10.3109\/10428194.2014.951848"},{"issue":"15","key":"818_CR20","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1182\/blood-2015-05-643601","volume":"126","author":"SE Karol","year":"2015","unstructured":"Karol SE, Yang W, Van Driest SL, Chang TY, Kaste S, Bowton E, et al. Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. Blood. 2015;126(15):1770\u20136.","journal-title":"Blood"},{"issue":"8","key":"818_CR21","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1182\/blood-2010-10-311969","volume":"117","author":"JD Kawedia","year":"2011","unstructured":"Kawedia JD, Kaste SC, Pei D, Panetta JC, Cai X, Cheng C, et al. Pharmacokinetic, pharmacodynamic, and Pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood. 2011;117(8):2340\u20137. quiz 2556.","journal-title":"Blood"},{"issue":"6","key":"818_CR22","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/pbc.22163","volume":"53","author":"S Marino","year":"2009","unstructured":"Marino S, Verzegnassi F, Tamaro P, Stocco G, Bartoli F, Decorti G, et al. Response to glucocorticoids and toxicity in childhood acute lymphoblastic leukemia: role of polymorphisms of genes involved in glucocorticoid response. Pediatr Blood Cancer. 2009;53(6):984\u201391.","journal-title":"Pediatr Blood Cancer"},{"key":"818_CR23","doi-asserted-by":"publisher","first-page":"634956","DOI":"10.3389\/fphar.2021.634956","volume":"12","author":"H Liu","year":"2021","unstructured":"Liu H, Li Z, Qiu F, Li C, Lin X, He Y, et al. Association between NR3C1 mutations and glucocorticoid resistance in children with acute lymphoblastic leukemia. Front Pharmacol. 2021;12:634956.","journal-title":"Front Pharmacol"},{"key":"818_CR24","doi-asserted-by":"crossref","unstructured":"Zhang J, Zeng L, Wang Y, Pan J, Li X, Feng B, et al. Gene mutations related to glucocorticoid resistance in pediatric acute lymphoblastic leukemia. Front Pediatr. 2022;10:831229.","DOI":"10.3389\/fped.2022.831229"},{"key":"818_CR25","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1038\/leu.2014.80","volume":"28","author":"IM Aries","year":"2014","unstructured":"Aries IM, Jerchel IS, Dungen RE, Berk LC, Boer JM, Horstmann MA, et al. EMP1, a novel poor prognostic factor in pediatric leukemia regulates prednisolone resistance, cell proliferation, migration and adhesion. Leukemia. 2014;28:1828\u201337.","journal-title":"Leukemia"},{"key":"818_CR26","doi-asserted-by":"crossref","unstructured":"Paugh SW, Bonten EJ, Savic D, Ramsey LB, Thierfelder WE, Gurung P, et al. NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nat Genet. 2015;47(6):607\u201314.","DOI":"10.1038\/ng.3283"},{"issue":"10","key":"818_CR27","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1038\/s41375-022-01685-z","volume":"36","author":"BP Bergeron","year":"2022","unstructured":"Bergeron BP, Diedrich JD, Zhang Y, Barnett KR, Dong Q, Ferguson DC, et al. Epigenomic profiling of glucocorticoid responses identifies cis-regulatory disruptions impacting steroid resistance in childhood acute lymphoblastic leukemia. Leukemia. 2022;36(10):2374\u201383.","journal-title":"Leukemia"},{"key":"818_CR28","doi-asserted-by":"crossref","unstructured":"Gibson A, Hernandez C, Tejada FNH, Kawedia J, Rytting M, Cuglievan B. Asparaginase-associated pancreatitis in pediatric patients with acute lymphoblastic leukemia: current perspectives. Pediatr Drugs. 2021;23(5):457\u201363.","DOI":"10.1007\/s40272-021-00463-1"},{"issue":"27","key":"818_CR29","doi-asserted-by":"publisher","first-page":"43752","DOI":"10.18632\/oncotarget.17959","volume":"8","author":"R Abaji","year":"2017","unstructured":"Abaji R, Gagn\u00e9 V, Xu CJ, Spinella JF, Ceppi F, Laverdi\u00e8re C, et al. Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients. Oncotarget. 2017;8(27):43752\u201367.","journal-title":"Oncotarget"},{"key":"818_CR30","doi-asserted-by":"crossref","unstructured":"Fernandez CA, Smith C, Yang W, Mullighan CG, Qu C, Larsen E, et al. Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. Blood. 2015 July 2;126(1):69\u201375.","DOI":"10.1182\/blood-2015-02-628800"},{"issue":"3","key":"818_CR31","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3324\/haematol.2018.199356","volume":"104","author":"BO Wolthers","year":"2019","unstructured":"Wolthers BO, Frandsen TL, Patel CJ, Abaji R, Attarbaschi A, Barzilai S, et al. Trypsin-encoding PRSS1-PRSS2 variations influence the risk of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a Ponte Di Legno toxicity working group report. Haematologica. 2019;104(3):556\u201363.","journal-title":"Haematologica"},{"issue":"2","key":"818_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/clpt.2010.94","volume":"88","author":"SH Chen","year":"2010","unstructured":"Chen SH, Pei D, Yang W, Cheng C, Jeha S, Cox NJ, et al. Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther. 2010;88(2):191\u20136.","journal-title":"Clin Pharmacol Ther"},{"key":"818_CR33","doi-asserted-by":"crossref","unstructured":"Anderson SJ, Scott EN, Raack EJ, Chang W, C\u00f3rdova-Delgado M, Trueman JN, et al. Amino acid stress response genes contribute to a 25\u2010Fold increased risk of L\u2010asparaginase\u2013induced hypersensitivity. Pediatr Blood Cancer. 2025;72(6):e31668.","DOI":"10.1002\/pbc.31668"},{"issue":"6","key":"818_CR34","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/cpt.756","volume":"102","author":"A Gutierrez-Camino","year":"2017","unstructured":"Gutierrez-Camino A, Martin-Guerrero I, Garcia-Orad A. PNPLA3 rs738409 and hepatotoxicity in children with B-cell acute lymphoblastic leukemia: A validation study in a Spanish cohort. Clin Pharmacol Ther. 2017;102(6):906\u2013906.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"818_CR35","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/bjh.15660","volume":"184","author":"SG H\u00f8jfeldt","year":"2019","unstructured":"H\u00f8jfeldt SG, Wolthers BO, Tulstrup M, Abrahamsson J, Gupta R, Harila-Saari A, et al. Genetic predisposition to PEG-asparaginase hypersensitivity in children treated according to NOPHO ALL2008. Br J Haematol. 2019;184(3):405\u201317.","journal-title":"Br J Haematol"},{"key":"818_CR36","doi-asserted-by":"crossref","unstructured":"Liu Y, Yang W, Smith CA, Cheng C, Karol SE, Larsen EC, et al. Class II human leukocyte antigen variants associate with risk of Pegaspargase hypersensitivity. Clin Pharmacol Ther. 2021 Sept;110(3):794\u2013802.","DOI":"10.1002\/cpt.2241"},{"issue":"1","key":"818_CR37","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13045-021-01201-3","volume":"14","author":"GT Chua","year":"2021","unstructured":"Chua GT, Rosa Duque JS, Cheuk DKL, Leung AWK, Wong WHS, Liu APY, et al. HLA alleles associated with asparaginase hypersensitivity in Chinese children. J Hematol OncolJ Hematol Oncol. 2021;14(1):182.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"8","key":"818_CR38","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1182\/blood-2014-03-563742","volume":"124","author":"CA Fernandez","year":"2014","unstructured":"Fernandez CA, Smith C, Yang W, Dat\u00e9 M, Bashford D, Larsen E, et al. HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. Blood. 2014;124(8):1266\u201376.","journal-title":"Blood"},{"key":"818_CR39","doi-asserted-by":"crossref","unstructured":"Gagn\u00e9 V, St-Onge P, Beaulieu P, Laverdi\u00e8re C, Leclerc JM, Tran TH, et al. HLA alleles associated with asparaginase hypersensitivity in childhood ALL: a report from the DFCI consortium. Pharmacogenomics. 2020;21(8):541\u20137.","DOI":"10.2217\/pgs-2019-0195"},{"issue":"17","key":"818_CR40","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.2217\/pgs-2021-0107","volume":"22","author":"S Liu","year":"2021","unstructured":"Liu S, Gao C, Wu Y, Lin W, Li J, Xue T, et al. HLA-DRB1 *16:02 is associated with PEG-Asparaginase hypersensitivity. Pharmacogenomics. 2021;22(17):1135\u201342.","journal-title":"Pharmacogenomics"},{"key":"818_CR41","doi-asserted-by":"crossref","unstructured":"Wu S, Wang M, Alqahtani A, Lou M, Stock W, Bhojwani D, et al. Hispanic ethnicity and the rs4880 variant in SOD2 are associated with elevated liver enzymes and bilirubin levels in children receiving asparaginase-containing chemotherapy for acute lymphoblastic leukemia. Biomed Pharmacother. 2022;150:113000.","DOI":"10.1016\/j.biopha.2022.113000"},{"issue":"21","key":"818_CR42","doi-asserted-by":"publisher","first-page":"4815","DOI":"10.3390\/jcm10214815","volume":"10","author":"T Bartram","year":"2021","unstructured":"Bartram T, Sch\u00fctte P, M\u00f6ricke A, Houlston RS, Ellinghaus E, Zimmermann M, et al. Genetic variation in ABCC4 and CFTR and acute pancreatitis during treatment of pediatric acute lymphoblastic leukemia. J Clin Med. 2021;10(21):4815.","journal-title":"J Clin Med"},{"key":"818_CR43","doi-asserted-by":"publisher","first-page":"1493362","DOI":"10.3389\/fped.2024.1493362","volume":"12","author":"H Zhou","year":"2024","unstructured":"Zhou H, Lu J, Wang T, Gu X, Li X, Zhao J. Acute pancreatitis following asparaginase treatment in pediatric acute lymphoblastic leukemia with a heterozygous SPINK1 c.194\u2009+\u20092T\u2009>\u2009C intronic variant: a case report. Front Pediatr. 2024;12:1493362.","journal-title":"Front Pediatr"},{"issue":"3","key":"818_CR44","doi-asserted-by":"publisher","first-page":"e628","DOI":"10.1097\/MPH.0000000000002292","volume":"44","author":"RL Nielsen","year":"2022","unstructured":"Nielsen RL, Wolthers BO, Helenius M, Albertsen BK, Clemmensen L, Nielsen K, et al. Can machine learning models predict Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2022;44(3):e628\u201336.","journal-title":"J Pediatr Hematol Oncol"},{"key":"818_CR45","doi-asserted-by":"crossref","unstructured":"Aminkeng F, Bhavsar AP, Visscher H, Rassekh SR, Li Y, Lee JW, et al. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat Genet. 2015;47(9):1079\u201384.","DOI":"10.1038\/ng.3374"},{"key":"818_CR46","doi-asserted-by":"crossref","unstructured":"Petrykey K, Rezgui AM, Guern ML, Beaulieu P, St-Onge P, Drouin S, et al. Genetic factors in treatment-related cardiovascular complications in survivors of childhood acute lymphoblastic leukemia. Pharmacogenomics. 2021 Sept;22(14):885\u2013901.","DOI":"10.2217\/pgs-2021-0067"},{"issue":"8","key":"818_CR47","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1002\/pbc.24505","volume":"60","author":"H Visscher","year":"2013","unstructured":"Visscher H, Ross CJD, Rassekh SR, Sandor GSS, Caron HN, van Dalen EC, et al. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer. 2013;60(8):1375\u201381.","journal-title":"Pediatr Blood Cancer"},{"issue":"S1","key":"818_CR48","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/bcpt.13593","volume":"130","author":"CM Loucks","year":"2022","unstructured":"Loucks CM, Yan K, Tanoshima R, Ross CJD, Rassekh SR, Carleton BC. Pharmacogenetic testing to guide therapeutic decision-making and improve outcomes for children undergoing anthracycline\u2010based chemotherapy. Basic Clin Pharmacol Toxicol. 2022;130(S1):95\u20139.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"818_CR49","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1186\/s12885-018-4629-6","volume":"18","author":"JC S\u00e1gi","year":"2018","unstructured":"S\u00e1gi JC, Egyed B, Kelemen A, Kutszegi N, Hegyi M, G\u00e9zsi A, et al. Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma. BMC Cancer. 2018;18(1):704.","journal-title":"BMC Cancer"},{"issue":"6","key":"818_CR50","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/tpj.2015.63","volume":"16","author":"M Krajinovic","year":"2016","unstructured":"Krajinovic M, Elbared J, Drouin S, Bertout L, Rezgui A, Ansari M, et al. Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2016;16(6):530\u20135.","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"818_CR51","doi-asserted-by":"publisher","first-page":"23757","DOI":"10.1038\/s41598-021-03208-9","volume":"11","author":"S Aslam","year":"2021","unstructured":"Aslam S, Ameer S, Shabana NA, Ahmed M. Pharmacogenetics of induction therapy-related toxicities in childhood acute lymphoblastic leukemia patients treated with UKALL 2003 protocol. Sci Rep. 2021;11(1):23757.","journal-title":"Sci Rep"},{"issue":"1","key":"818_CR52","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41598-017-00075-1","volume":"7","author":"SL Leong","year":"2017","unstructured":"Leong SL, Chaiyakunapruk N, Lee SWH. Candidate gene association studies of Anthracycline-induced cardiotoxicity: A systematic review and Meta-analysis. Sci Rep. 2017;7(1):39.","journal-title":"Sci Rep"},{"issue":"1","key":"818_CR53","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1042\/CBI20110264","volume":"36","author":"AF Semsei","year":"2012","unstructured":"Semsei AF, Erdelyi DJ, Ungvari I, Csagoly E, Hegyi MZ, Kiszel PS, et al. ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia. Cell Biol Int. 2012;36(1):79\u201386.","journal-title":"Cell Biol Int"},{"key":"818_CR54","doi-asserted-by":"crossref","unstructured":"Hellmann F, V\u00f6ller S, Krischke M, Jamieson D, Andr\u00e9 N, Bisogno G, et al. Genetic polymorphisms affecting cardiac biomarker concentrations in children with cancer: an analysis from the European Paediatric Oncology Off-patents Medicines Consortium (EPOC) trial. Eur J Drug Metab Pharmacokinet. 2020;45(3):413\u201322.","DOI":"10.1007\/s13318-019-00592-6"},{"key":"818_CR55","doi-asserted-by":"crossref","unstructured":"Lopez-Lopez E, Gutierrez-Camino A, Bilbao-Aldaiturriaga N, Pombar-Gomez M, Martin-Guerrero I, Garcia-Orad A. Pharmacogenetics of childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014 July;15(10):1383\u201398.","DOI":"10.2217\/pgs.14.106"},{"key":"818_CR56","doi-asserted-by":"crossref","unstructured":"Wu C, Li W. Genomics and pharmacogenomics of pediatric acute lymphoblastic leukemia. Crit Rev Oncol Hematol. 2018;1:126:100\u201311.","DOI":"10.1016\/j.critrevonc.2018.04.002"},{"issue":"3","key":"818_CR57","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/cpt.463","volume":"101","author":"C Liu","year":"2017","unstructured":"Liu C, Yang W, Pei D, Cheng C, Smith C, Landier W, et al. Genomewide approach validates thiopurine methyltransferase activity is a Monogenic Pharmacogenomic trait. Clin Pharmacol Ther. 2017;101(3):373\u201381.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"818_CR58","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/cpt.1304","volume":"105","author":"MV Relling","year":"2019","unstructured":"Relling MV, Schwab M, Whirl-Carrillo M, Suarez-Kurtz G, Pui CH, Stein CM, et al. Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther. 2019;105(5):1095\u2013105.","journal-title":"Clin Pharmacol Ther"},{"key":"818_CR59","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s00535-015-1142-4","volume":"51","author":"A Asada","year":"2016","unstructured":"Asada A, Nishida A, Shioya M, Imaeda H, Inatomi O, Bamba S, et al. NUDT15 R139C- related thiopurine leukocytopenia is mediated by 6-thioguanine nucleotide-independent mechanism in Japanese patients with inflammatory bowel disease. J Gastroenterol. 2016;51:22\u20139.","journal-title":"J Gastroenterol"},{"key":"818_CR60","doi-asserted-by":"crossref","unstructured":"Kakuta Y, Naito T, Onodera M, Kuroha M, Kimura T, Shiga H, et al. NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD. Pharmacogenomics J. 2016;16(3):280\u20135.","DOI":"10.1038\/tpj.2015.43"},{"key":"818_CR61","doi-asserted-by":"crossref","unstructured":"Kakuta Y, Kawai Y, Okamoto D, Takagawa T, Ikeya K, Sakuraba H, et al. NUDT15 codon 139 is the best Pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study. J Gastroenterol. 2018;53(9):1065\u201378.","DOI":"10.1007\/s00535-018-1486-7"},{"issue":"4","key":"818_CR62","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/ng.3508","volume":"48","author":"T Moriyama","year":"2016","unstructured":"Moriyama T, Nishii R, Perez-Andreu V, Yang W, Klussmann FA, Zhao X, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet. 2016;48(4):367\u201373.","journal-title":"Nat Genet"},{"issue":"11","key":"818_CR63","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1200\/JCO.2014.59.4671","volume":"33","author":"JJ Yang","year":"2015","unstructured":"Yang JJ, Landier W, Yang W, Liu C, Hageman L, Cheng C, et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol. 2015;33(11):1235\u201342.","journal-title":"J Clin Oncol"},{"key":"818_CR64","doi-asserted-by":"crossref","unstructured":"Yang SK, Hong M, Baek J, Choi H, Zhao W, Jung Y, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 2014;46(9):1017\u201320.","DOI":"10.1038\/ng.3060"},{"issue":"3","key":"818_CR65","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1080\/08880018.2021.1973628","volume":"39","author":"POL Fan","year":"2022","unstructured":"Fan POL, Leung KT, Chan KYY, Leung AWK, Lam GKS, Chow TTW, et al. ABCC4, ITPA, NUDT15, TPMT and their interaction as genetic predictors of 6-mercaptopurine intolerance in Chinese patients with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2022;39(3):254\u201366.","journal-title":"Pediatr Hematol Oncol"},{"issue":"2","key":"818_CR66","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/FPC.0000000000000453","volume":"32","author":"T Moriyama","year":"2022","unstructured":"Moriyama T, Yang W, Smith C, Pui CH, Evans WE, Relling MV, et al. Comprehensive characterization of Pharmacogenetic variants in TPMT and NUDT15 in children with acute lymphoblastic leukemia. Pharmacogenet Genomics. 2022;32(2):60\u20136.","journal-title":"Pharmacogenet Genomics"},{"issue":"5","key":"818_CR67","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/jnci\/djae004","volume":"116","author":"M Maillard","year":"2024","unstructured":"Maillard M, Nishii R, Yang W, Hoshitsuki K, Chepyala D, Lee SHR, et al. Additive effects of TPMT and NUDT15 on thiopurine toxicity in children with acute lymphoblastic leukemia across multiethnic populations. JNCI J Natl Cancer Inst. 2024;116(5):702\u201310.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"10","key":"818_CR68","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2217\/PGS.15.62","volume":"16","author":"MS Hareedy","year":"2015","unstructured":"Hareedy MS, El Desoky ES, Woillard JB, Thabet RH, Ali AM, Marquet P, et al. Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients. Pharmacogenomics. 2015;16(10):1119\u201334.","journal-title":"Pharmacogenomics"},{"key":"818_CR69","doi-asserted-by":"crossref","unstructured":"Krishnamurthy P, Schwab M, Takenaka K, Nachagari D, Morgan J, Leslie M, et al. Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res. 2008;68(13):4983\u20139.","DOI":"10.1158\/0008-5472.CAN-07-6790"},{"key":"818_CR70","doi-asserted-by":"crossref","unstructured":"Guo HL, Zhao YT, Wang WJ, Dong N, Hu YH, Zhang YY, et al. Optimizing thiopurine therapy in children with acute lymphoblastic leukemia: a promising MINT sequencing strategy and therapeutic DNA-TG monitoring. Front Pharmacol. 2022;13:941182.","DOI":"10.3389\/fphar.2022.941182"},{"issue":"7","key":"818_CR71","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2217\/pgs-2020-0193","volume":"22","author":"R Ramalingam","year":"2021","unstructured":"Ramalingam R, Kaur H, Scott JX, Sneha LM, Arun Kumar GP, Srinivasan A, et al. Pharmacogenetic evaluation of 6-Mercaptopurine-Mediated toxicity in pediatric acute lymphoblastic leukemia patients from a South Indian population. Pharmacogenomics. 2021;22(7):401\u201311.","journal-title":"Pharmacogenomics"},{"issue":"2","key":"818_CR72","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/tpj.2017.12","volume":"18","author":"Y Tanaka","year":"2018","unstructured":"Tanaka Y, Nakadate H, Kondoh K, Nakamura K, Koh K, Manabe A. Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2018;18(2):275\u201380.","journal-title":"Pharmacogenomics J"},{"key":"818_CR73","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3389\/fphar.2020.00267","volume":"11","author":"M Cao","year":"2020","unstructured":"Cao M, Yin D, Qin Y, Liao F, Su Y, Xia X, et al. Screening of novel Pharmacogenetic candidates for Mercaptopurine-Induced toxicity in patients with acute lymphoblastic leukemia. Front Pharmacol. 2020;11:267.","journal-title":"Front Pharmacol"},{"key":"818_CR74","doi-asserted-by":"crossref","unstructured":"Kim H, Seo H, Park Y, Min BJ, Seo ME, Park KD, et al. APEX1 polymorphism and mercaptopurine-related early onset neutropenia in pediatric acute lymphoblastic leukemia. Cancer Res Treat. 2018;50(3):823\u201334.","DOI":"10.4143\/crt.2017.351"},{"key":"818_CR75","doi-asserted-by":"publisher","first-page":"1159307","DOI":"10.3389\/fphar.2023.1159307","volume":"14","author":"AM Ali","year":"2023","unstructured":"Ali AM, Adam H, Hailu D, Engidawork E, Howe R, Abula T, et al. Genetic variants of genes involved in thiopurine metabolism pathway are associated with 6-mercaptopurine toxicity in pediatric acute lymphoblastic leukemia patients from Ethiopia. Front Pharmacol. 2023;14:1159307.","journal-title":"Front Pharmacol"},{"issue":"2","key":"818_CR76","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2217\/pgs-2017-0153","volume":"19","author":"F Ceppi","year":"2018","unstructured":"Ceppi F, Gagn\u00e9 V, Douyon L, Quintin CJ, Colombini A, Parasole R, et al. DNA variants in DHFR gene and response to treatment in children with childhood B ALL: revisited in AIEOP-BFM protocol. Pharmacogenomics. 2018;19(2):105\u201312.","journal-title":"Pharmacogenomics"},{"issue":"7","key":"818_CR77","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1182\/blood-2007-09-110593","volume":"111","author":"S Dulucq","year":"2008","unstructured":"Dulucq S, St-Onge G, Gagn\u00e9 V, Ansari M, Sinnett D, Labuda D, et al. DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL. Blood. 2008;111(7):3692\u2013700.","journal-title":"Blood"},{"key":"818_CR78","doi-asserted-by":"crossref","unstructured":"Liu SG, Gao C, Zhang RD, Zhao XX, Cui L, Li WJ, et al. Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia. Oncotarget. 2017;6(23):37761\u201372.","DOI":"10.18632\/oncotarget.17781"},{"issue":"4","key":"818_CR79","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3390\/genes11040468","volume":"11","author":"N Kotur","year":"2020","unstructured":"Kotur N, Lazic J, Ristivojevic B, Stankovic B, Gasic V, Dokmanovic L, et al. Pharmacogenomic markers of methotrexate response in the consolidation phase of pediatric acute lymphoblastic leukemia treatment. Genes. 2020;11(4):468.","journal-title":"Genes"},{"issue":"2","key":"818_CR80","doi-asserted-by":"publisher","first-page":"e70136","DOI":"10.1111\/cts.70136","volume":"18","author":"S Braidotti","year":"2025","unstructured":"Braidotti S, Zudeh G, Franca R, Kiren V, Colombini A, Bettini LR, et al. The role of candidate polymorphisms in drug transporter genes on High-Dose methotrexate in the consolidation phase of the AIEOP\u2010BFM ALL 2009 protocol. Clin Transl Sci. 2025;18(2):e70136.","journal-title":"Clin Transl Sci"},{"key":"818_CR81","doi-asserted-by":"publisher","first-page":"1480657","DOI":"10.3389\/fphar.2024.1480657","volume":"15","author":"JY Choi","year":"2024","unstructured":"Choi JY, Kwon H, Kim H, Hong KT, Ma Y, Koh KN, et al. Novel genomic variants influencing methotrexate delayed clearance in pediatric patients with acute lymphoblastic leukemia. Front Pharmacol. 2024;15:1480657.","journal-title":"Front Pharmacol"},{"issue":"3","key":"818_CR82","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/ng.2532","volume":"45","author":"L Holmfeldt","year":"2013","unstructured":"Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013;45(3):242\u201352.","journal-title":"Nat Genet"},{"key":"818_CR83","doi-asserted-by":"crossref","unstructured":"Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;11(11):1005\u201315.","DOI":"10.1056\/NEJMoa1403088"},{"issue":"8","key":"818_CR84","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab Ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740\u201353.","journal-title":"N Engl J Med"},{"issue":"8","key":"818_CR85","doi-asserted-by":"publisher","first-page":"563","DOI":"10.6004\/jnccn.2024.0051","volume":"22","author":"B Shah","year":"2024","unstructured":"Shah B, Mattison RJ, Abboud R, Abdelmessieh P, Aldoss I, Burke PW, et al. Acute lymphoblastic Leukemia, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN. 2024;22(8):563\u201376.","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"issue":"3","key":"818_CR86","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/s41375-022-01806-8","volume":"37","author":"SL Ryan","year":"2023","unstructured":"Ryan SL, Peden JF, Kingsbury Z, Schwab CJ, James T, Polonen P, et al. Whole genome sequencing provides comprehensive genetic testing in childhood B-cell acute lymphoblastic leukaemia. Leukemia. 2023;37(3):518\u201328.","journal-title":"Leukemia"},{"issue":"3","key":"818_CR87","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s43018-020-0037-3","volume":"1","author":"RJ Autry","year":"2020","unstructured":"Autry RJ, Paugh SW, Carter R, Shi L, Liu J, Ferguson DC, et al. Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nat Cancer. 2020;1(3):329\u201344.","journal-title":"Nat Cancer"},{"key":"818_CR88","doi-asserted-by":"crossref","unstructured":"Ferguson DC, McCorkle JR, Barnett KR, Bonten EJ, Bergeron BP, Bhattarai KR, et al. Amino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia. Blood Adv. 2022;6(11):3386\u201397.","DOI":"10.1182\/bloodadvances.2022006965"},{"key":"818_CR89","doi-asserted-by":"crossref","unstructured":"Gebhard A, Lilienthal P, Metzler M, Rauh M, Sager S, Schmiegelow K, et al. Pharmacokinetic\u2013pharmacodynamic modeling of maintenance therapy for childhood acute lymphoblastic leukemia. Sci Rep. 2023;20(1):11749.","DOI":"10.1038\/s41598-023-38414-0"},{"issue":"4","key":"818_CR90","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1111\/bcp.14426","volume":"88","author":"T Mizuno","year":"2022","unstructured":"Mizuno T, Dong M, Taylor ZL, Ramsey LB, Vinks AA. Clinical implementation of pharmacogenetics and model-informed precision dosing to improve patient care. Br J Clin Pharmacol. 2022;88(4):1418\u201326.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"818_CR91","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1515\/biol-2021-0121","volume":"16","author":"Y Shen","year":"2021","unstructured":"Shen Y, Wang Z, Zhou F, Jin R. The influence of MTHFR genetic polymorphisms on methotrexate therapy in pediatric acute lymphoblastic leukemia. Open Life Sci. 2021;16(1):1203\u201312.","journal-title":"Open Life Sci"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00818-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-025-00818-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00818-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:14:19Z","timestamp":1768342459000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-025-00818-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["818"],"URL":"https:\/\/doi.org\/10.1007\/s43440-025-00818-2","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AI-use declaration:\u00a0 Portions of this manuscript were reviewed and optimized for grammar and readability using the AI tools Grammarly and ChatGPT. All modifications suggested by the tools were reviewed and accepted or rejected by the author based on the context and intended meaning of the text.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}